Recently, global medical technology company BD (Becton, Dickinson and Company) announced that the company has completed a global acquisition of Bard for a total of $24 billion. The acquisition marks BD as the new leader in the medical industry , with annual revenues rising to approximately $16 billion.
The new BD will be uniquely positioned to better help patients improve their treatment and help healthcare professionals improve their medical services. BD will expand its full-process overall solution based on its current leadership in drug management and infection prevention. In addition, Bard's strong product portfolio and innovative channels will enable BD to gain more opportunities in the rapidly growing clinical business arena. After the merger, the new BD will also gain more business development in markets outside the United States.
“This is a historic day for BD because we are welcoming Bard and its 16,000 employees.†VIN Chairman and CEO Vince Forlenza said: “The two companies are more than 100 We have been committed to leading the world in health and providing support services to front-line personnel in the medical industry. We look forward to continuing to lead the industry through product technology innovation and partnerships to bring more valuable solutions to our customers and patients. â€
Pursuant to the terms of the transaction, as the acquisition is completed, Bard will become a wholly-owned subsidiary of BD, and the ordinary shares of the company in circulation will be converted into (1) $222.93 in cash (no interest), and (2) 0.5077 shares. BD ordinary stock rights. After the completion of the acquisition, the company's shares will be closed and will be delisted from the New York Stock Exchange.
BD forecasts that, in addition to transaction-related expenses, the acquisition will not have a significant impact on the performance of the first quarter of FY 2018 (as of December 31, 2017).
In addition, BD also predicts that the acquisition will enable BD stocks to achieve low single-digit growth in earnings per share in FY 2018 and high single-digit growth in FY 2019. BD will update its entire FY18Y18 earnings forecast on its first financial quarterly earnings conference call to reflect the expected growth of BD's revenue for the entire 2018 fiscal year (as of September 30, 2018).
From the second quarter of fiscal year 2018, BD's earnings report will be added to the intervention business segment. This section covers most of Bard's product lines. The rest of Bard's products are classified in the medical business sector. (China News Network)
Best Neck Massager,Shiatsu Neck Massager,Neck Relax Massager,Best Massage For Neck Pain
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizonscares.com